Back to dashboard
CommercialCoverageMedium impact

Genetic Testing for Alzheimer Disease

Blue Cross & Blue Shield of Mississippi·MS · Neurology, Family Medicine, Internal Medicine +1 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

BCBS Mississippi has updated their medical policy A.2.04.13 for genetic testing coverage in Alzheimer Disease, providing detailed criteria for when genetic testing (APOE, PSEN1, PSEN2, APP, TREM2, SORL1 variants) may be covered. This policy establishes specific clinical guidelines for early-onset vs late-onset AD genetic testing.

Action Required

Action needed
Immediately: Review updated policy A.2.04.13 for genetic testing in Alzheimer Disease. Billing team should verify coverage criteria before submitting claims for genetic testing related to AD - early-onset familial AD (before age 65) has different testing criteria than late-onset AD. Ensure clinical documentation supports appropriate genetic variant testing (APP, PSEN1, PSEN2 for early-onset; APOE ε4, TREM2, SORL1 for late-onset cases).

Related policy hubs